Retatrutide is hypothesized to act as a triple receptor agonist in preclinical models, interacting with pathways commonly associated with glucagon, GLP-1 (glucagon-like peptide-1), and GIP (glucose-dependent insulinotropic polypeptide)
From a molecular research perspective, Retatrutide provides an opportunity to investigate how multiple peptide hormone systems interact rather than functioning independently
[DOI] [PMC free article] [PubMed] [Google Scholar] 78.Bizino M.B., Jazet I.M., Westenberg J.J.M., van Eyk H.J., Paiman E.H.M., Smit J.W.A., Lamb H.J
Lunch (12:00 PM): 35g protein
Its likely the drug will increase accessibility, remove barriers and lead to a rising number of patients using GLP-1s to lose and manage their weight
Okay, so what would be, you know, so this is a good foundation for what these drugs are, how they work, you know, how they may help somebody short-term lose weight, but you know, what would be some factors to consider if somebody wanted to lose weight and was looking at this as an option
